Ozempic and retatrutide are not the same class of drug, and that difference shapes everything else. Ozempic is the brand name for semaglutide, a single-target GLP-1 receptor agonist made by Novo Nordisk and FDA-approved for type 2 diabetes since December 2017. Retatrutide is an investigational triple-hormone-receptor agonist from Eli Lilly that is still in phase 3 trials and is not approved or commercially available anywhere in 2026. In head-to-head terms, retatrutide produced larger weight loss in its trials (about 24% over 48 weeks at the top dose) than semaglutide does (about 15% over 68 weeks at the weight-loss dose), but you can get Ozempic from a pharmacy today and you cannot legally get retatrutide outside a clinical trial.
This guide breaks down how the two compare on mechanism, efficacy, dosing, side effects, availability, and cost, and clears up the common confusion between Ozempic and Wegovy.
Quick answer: the core difference
- Ozempic = semaglutide. One mechanism: it mimics GLP-1. Approved for type 2 diabetes glycemic control. The same molecule at a higher dose is sold as Wegovy for weight management.
- Retatrutide = "triple G." Three mechanisms in one molecule: GIP, GLP-1, and glucagon receptor agonism. It is experimental, with no FDA decision yet.
If your decision is "what can I be prescribed now," Ozempic (or Wegovy) is the real option. If your question is "what is coming next and how much better could it be," that is the retatrutide story.
Mechanism: one hormone vs three
Semaglutide activates a single receptor, GLP-1. That alone slows gastric emptying, increases insulin secretion when glucose is high, suppresses glucagon, and reduces appetite signaling in the brain. It is a clean, well-characterized single-agonist drug.
Retatrutide is a single molecule engineered to hit three receptors at once:
- GLP-1 for appetite suppression and glucose-dependent insulin release, the same pathway Ozempic uses.
- GIP, a second incretin hormone, the pathway shared with tirzepatide (Mounjaro and Zepbound).
- Glucagon, which is the differentiator. Glucagon receptor agonism can raise energy expenditure and influence hepatic fat metabolism, which is thought to add to the weight-loss effect rather than just curbing intake.
That third lever is why retatrutide is sometimes described as the most aggressive metabolic agent in development. For a deeper breakdown, see our explainers on what retatrutide is and the retatrutide mechanism of action.
Side-by-side comparison
| Feature | Retatrutide | Ozempic (semaglutide) |
|---|---|---|
| Maker | Eli Lilly | Novo Nordisk |
| Drug class | Triple agonist (GIP / GLP-1 / glucagon) | Single GLP-1 receptor agonist |
| FDA status (2026) | Investigational, phase 3 (TRIUMPH program) | Approved for type 2 diabetes since 2017 |
| Primary approved use | None yet | Glycemic control in type 2 diabetes |
| Weight-loss data | ~24.2% at 48 weeks (12 mg, phase 2) | ~14.9% at 68 weeks (2.4 mg, STEP 1, as Wegovy) |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Doses studied / sold | 1, 4, 8, 12 mg (trial doses) | 0.25, 0.5, 1, 2 mg (commercial) |
| Availability | Not commercially available | Pharmacy with prescription |
| Insurance coverage | None | Often covered for diabetes |
Weight loss: what the trials actually showed
This is where the gap is widest, but the numbers come from different trials, so read them carefully.
Retatrutide (phase 2, NEJM 2023): In a randomized, double-blind, placebo-controlled phase 2 trial in adults with obesity, the 12 mg dose produced a mean weight reduction of 17.5% at 24 weeks and 24.2% at 48 weeks. Notably, the weight-loss curve had not plateaued when the trial ended, suggesting the ceiling may be higher. Phase 3 TRIUMPH program readouts reported through 2025 and 2026 have shown weight loss in a similar or higher range, but those results are still being finalized and have not led to approval. See our retatrutide clinical trial summary for the full data.
Semaglutide for weight loss: Ozempic itself is not approved for weight loss, but the identical molecule is. In the STEP 1 trial, Wegovy (semaglutide 2.4 mg) produced a mean weight change of -14.9% over 68 weeks versus -2.4% for placebo, with 86.4% of participants losing at least 5% of body weight. At Ozempic's diabetes doses (up to 2 mg), weight loss is generally smaller because the dose is lower and the population is different.
The practical takeaway: retatrutide's trial weight loss is meaningfully larger, on the order of 9 to 10 percentage points more than semaglutide at comparable timelines. But trial conditions are not real-world conditions, and one is approved while the other is not.
For a more granular look at retatrutide's trajectory, see retatrutide week by week and retatrutide before and after.
Blood sugar and diabetes
Ozempic was built for diabetes first. In the SUSTAIN trials, semaglutide lowered A1C by roughly 1.4% to 2.1% depending on dose, and a majority of patients on the 1 mg dose reached an A1C below 7%. This is its primary, approved indication.
Retatrutide also lowered A1C substantially in its type 2 diabetes phase 2 work, and the glucagon component raised early questions about glucose handling that the trials monitored closely. Glucagon can nudge blood sugar upward in isolation, so the trial design watched for whether the GLP-1 and GIP activity offset that effect, and the reported net result favored glucose lowering. Still, none of this has cleared regulatory review. Until phase 3 diabetes data are fully published and an approval is granted, retatrutide cannot be positioned as a diabetes treatment, and any comparison with Ozempic on glycemic control is provisional.
Dosing and titration
Both drugs are once-weekly subcutaneous injections, and both require slow dose escalation to limit nausea.
- Ozempic starts at 0.25 mg weekly for four weeks (a titration dose, not therapeutic), then steps to 0.5 mg, then 1 mg, and up to 2 mg if needed. The 2 mg dose was FDA-approved in March 2022.
- Retatrutide was studied at 1, 4, 8, and 12 mg weekly, with gradual escalation to the target dose. Because it is investigational, there is no official prescribing schedule. Our retatrutide dosage guide, dosage chart, and dosing schedule reflect trial protocols, not an approved label. Some people also ask about retatrutide microdosing, which is not a trial-validated approach.
A note on pharmacokinetics: both molecules are engineered for once-weekly dosing, and you can read more on retatrutide half-life if you want the detail.
Side effects
The side-effect profiles rhyme because both drugs work heavily through GLP-1. Gastrointestinal effects dominate.
Shared, most common effects:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Reduced appetite
For both drugs these effects are usually mild to moderate, dose-related, and worst during dose escalation. In retatrutide's phase 2 trial, GI events were the most common adverse events and were dose-dependent, which is the same pattern seen with semaglutide.
Where they may differ: retatrutide's glucagon activity introduced effects that the trials tracked closely, including dose-related increases in heart rate and changes in some metabolic markers. Whether these matter clinically will be judged on the phase 3 data and any eventual label. GLP-1 class warnings, such as the risk of pancreatitis, gallbladder issues, and the rodent-derived thyroid C-cell tumor warning, are relevant to semaglutide and are being evaluated for retatrutide. For more, see retatrutide side effects and is retatrutide safe.
Availability and legal status in 2026
This is the most important practical distinction.
- Ozempic is FDA-approved and dispensed by pharmacies with a prescription. Supply has been variable over the years, but it is a legitimate, available drug.
- Retatrutide is not approved by the FDA or any major regulator. It is not sold in pharmacies, not covered by insurance, and cannot be legally prescribed outside a clinical trial. Eli Lilly's TRIUMPH phase 3 program is ongoing, and approval is widely expected no earlier than 2027 pending results and review. Our when will retatrutide be available page tracks the timeline.
Because demand is high, a gray market of compounded retatrutide and research-chemical sellers has appeared. Buying retatrutide without a prescription or from unverified sources carries real risks: no quality control, no dosing oversight, and no legal protection. We do not recommend it.
Cost
Ozempic has an established but high list price in the United States, often around the four-figures-per-month range before insurance, with most insured diabetes patients paying far less through coverage and manufacturer savings programs.
Retatrutide has no list price because it is not for sale. Any number you see attached to gray-market or compounded retatrutide is set by the seller, not a manufacturer or insurer, and tells you nothing about safety or potency. Once approved, pricing will be set by Eli Lilly and shaped by competition with tirzepatide and semaglutide, and by whatever insurance and savings programs eventually attach to it. For now, the only honest cost comparison is that Ozempic has a real, knowable price and retatrutide does not. See retatrutide cost for current estimates and caveats.
Which one fits which situation
- You have type 2 diabetes and want a proven, prescribable option now: Ozempic is purpose-built for this and is approved for it.
- You want maximum weight loss and are tracking what is coming: Retatrutide's trial data are the strongest in the class so far, but it is not yet an option you can act on.
- You want a weight-loss drug you can start today: Ozempic's molecule is approved for weight loss as Wegovy; that is the legitimate path, not off-label retatrutide.
It is also worth comparing retatrutide to its nearer competitors rather than only to a single GLP-1 agonist. See retatrutide vs tirzepatide (a dual agonist), retatrutide vs semaglutide (the same molecule as Ozempic, framed for weight loss), and survodutide vs retatrutide.
FAQ
Is retatrutide better than Ozempic? In trials, retatrutide produced larger weight loss (about 24% at 48 weeks vs about 15% at 68 weeks for semaglutide as Wegovy). But "better" depends on availability and approval, and retatrutide is still investigational while Ozempic is approved and prescribable.
Is retatrutide FDA-approved in 2026? No. As of 2026 retatrutide is in phase 3 (the TRIUMPH program) and has not been approved. It is not sold in pharmacies and cannot be legally prescribed outside a clinical trial.
Is Ozempic the same as Wegovy? Both are semaglutide from Novo Nordisk. Ozempic is approved for type 2 diabetes (doses up to 2 mg), while Wegovy is the same molecule at a higher 2.4 mg dose approved for weight management.
Can I switch from Ozempic to retatrutide? Not through normal medical channels, because retatrutide is not available by prescription. If it is approved in the future, switching would be a clinical decision based on your goals, response, and tolerance.
Why does retatrutide cause more weight loss than Ozempic? Retatrutide hits three receptors (GIP, GLP-1, and glucagon) instead of one. The added glucagon and GIP activity is thought to increase energy expenditure and appetite suppression beyond what GLP-1 alone achieves.
This article is for informational purposes only and is not medical advice. Talk to a qualified clinician before starting, stopping, or changing any medication.
